Gavin G Meredith1, Paul A Schkade2, Brian C Joondeph1,3. 1. Rocky Vista University College of Osteopathic Medicine, Parker, Colorado. 2. University of Colorado School of Medicine, Aurora, Colorado. 3. Colorado Retina Associates, PC, Denver, Colorado.
Abstract
PURPOSE: To describe the patient's allergic response to anti-vascular endothelial growth factor drugs after receiving intravitreal bevacizumab for choroidal neovascularization. METHODS: Clinical case report. RESULTS: Formal allergy evaluation revealed hypersensitivity to bevacizumab and ranibizumab, but not to pegaptanib or aflibercept. CONCLUSION: Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin. These chemical origins may allow patients to receive pegaptanib or aflibercept despite having allergy to bevacizumab or ranibizumab.
PURPOSE: To describe the patient's allergic response to anti-vascular endothelial growth factor drugs after receiving intravitreal bevacizumab for choroidal neovascularization. METHODS: Clinical case report. RESULTS: Formal allergy evaluation revealed hypersensitivity to bevacizumab and ranibizumab, but not to pegaptanib or aflibercept. CONCLUSION:Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin. These chemical origins may allow patients to receive pegaptanib or aflibercept despite having allergy to bevacizumab or ranibizumab.
Authors: Maddalena De Bernardo; Cristiana Stellato; Nicola Rosa; Ilaria De Pascale; Francesco Antonio Salzano Journal: Int J Immunopathol Pharmacol Date: 2020 Jan-Dec Impact factor: 3.219
Authors: Sara J Haug; Doan Luong Hien; Gunay Uludag; Than Trong Tuong Ngoc; Sherin Lajevardi; M Sohail Halim; Yasir J Sepah; Diana V Do; Arshad M Khanani Journal: Am J Ophthalmol Case Rep Date: 2020-03-31